Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Post by onions7777on May 05, 2018 8:38am
211 Views
Post# 27986676

Upward Momentum

Upward MomentumLooks like you guys had some upward movement! Good for you, I hope you get your money back. Not here to Bash, nor to Pump, just to give neutral info to the friends I have met here. Going through my emails and I thought I would share the most recent Reuters and Morningstar reports for NVCN, in case you don't receive them and are still trading with old estimated info.

Both reports have downgraded estimates now. Morningstar, the report I rely on the most has dropped the most. Reuters has dropped from a 5 Neutral rating to a 1 Negative rating over the past 4 weeks. 4000% 12 month estimated projection has now dropped to 1757%. The mean target price is now 0.72 compared to 1.88 last week with a new high of 1.56 and a low of .10

The 3 analyst strong buy rating has now dropped to 2 Strong Buy and 1 Hold. Keep in mind, larger companies have 10-30 analyst ratings, so I wouldn't rely too much on what 3 analysts say.

Even with the downgraded info, you can still make alot if you bought in at the right time. In my opinion this still is an undervalued stock and the only reason I'm not in is the manipulation and upcoming May news. I'm waiting to see how that pans out first.

I have included pics of my info. I'm not very good with uploading so I took a pic with my phone and posted on twitter. If the pics don't upload here you may have to click the links.

Good luck to everyone :)

[img]https://pbs.twimg.com/media/Dcbqq7lXcAA9I2c.jpg:large[/img]

[img]https://pbs.twimg.com/media/DcbquMcWAAATWHD.jpg:large[/img]

[img]https://pbs.twimg.com/media/DcbqxuaW4AA9AsT.jpg:large[/img]

[img]https://pbs.twimg.com/media/Dcbq82JWsAAney5.jpg:large[/img]
<< Previous
Bullboard Posts
Next >>